Alliance for Cancer Gene Therapy (ACGT) takes on solid tumor cancers

Alliance for Cancer Gene Therapy (ACGT), the nation’s only charitable organization dedicated exclusively to funding cancer cell and gene therapy research, is proud to announce the recipients of its 2018 research grants using innovative clinical approaches to find gene therapy treatments for solid cancers. Recipients of this year’s grants include: Joseph Glorioso, MD, PhD, of the University of Pittsburgh, and Gary Cohen, PhD, of the University of Pennsylvania, who are working together on a vaccine for melanoma; Stephan Matthias, MD, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, Washington, who is creating an injectable genetic agent to more effectively program T cell receptors; and David Reardon, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, who is developing a CAR T cell therapy for deadly brain cancer. The three grants are each in the amount of $500,000, paid over the next two or three years, depending on the time-frame of the research.

“This work represents the next generation of gene therapies,” noted Margaret Cianci, executive director of ACGT. “Two of the three grants fund crucial research leading to the development of cancer vaccines, among the most promising forms of gene therapy. These vaccines are not like traditional vaccines


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD